AzTrials
AzTrials

Urinary Bladder, OveractivePhase 4SAFINANCT00806494

UK Study Assessing Flexible Dose Fesoterodine in Adults

A Phase 4 study testing Fesoterodine in people with Urinary Bladder, Overactive, run by Pfizer at 39 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To explore the effects of fesoterodine when used in a flexible dose manner Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Urinary Bladder, Overactive
What is being tested?
Fesoterodine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
331 participants
Where
39 sitesUnited Kingdom
Study dates
Feb 2009to Jan 2010
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female >18 years old
  • OAB for >3 months

Who cannot join

  • Patients with conditions that would contraindicate for fesoterodine use
  • Patients with significant hepatic and renal disease or other significant unstable diseases.
  • OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

Trial locations and contacts

39 sites in 1 country.

39 sites in 1 country

United Kingdom39 sites
  • Pfizer Investigational Site

    Addlestone, Surrey, KT15 2BH

  • Pfizer Investigational Site

    Ashford, Middlesex, TW15 3EA

  • Pfizer Investigational Site

    Ayrshire, Scotland, KA12 0AY

  • Pfizer Investigational Site

    Baillieston, Glasgow, G69 7AD

  • Pfizer Investigational Site

    Bath, Somerset, BA1 2SR

  • Pfizer Investigational Site

    Bath, BA2 3HT

  • Pfizer Investigational Site

    Bath, BA2 4BY

  • Pfizer Investigational Site

    Bexhill-on-Sea, East Sussex, TN40 1JJ

  • Pfizer Investigational Site

    Blackpool, Lancashire, FY3 7EN

  • Pfizer Investigational Site

    Blackpool, Lancashire, FY4 3AD

  • Pfizer Investigational Site

    Bradford on Avon, Wiltshire, BA1 5DQ

  • Pfizer Investigational Site

    Bristol, BS2 8HW

  • Pfizer Investigational Site

    Bucks, HP22 5LB

  • Pfizer Investigational Site

    Chesterfield, Derbyshire, S40 4TF

  • Pfizer Investigational Site

    Chesterfield, Derbyshire, S44 5BL

  • Pfizer Investigational Site

    Chippenham, Wilts, SN14 8GT

  • Pfizer Investigational Site

    Crewe, Cheshire, CW1 4QJ

  • Pfizer Investigational Site

    Doncaster, South Yorkshire, DN9 1ND

  • Pfizer Investigational Site

    Ely, Cambridgeshire, CB7 5JD

  • Pfizer Investigational Site

    Falkirk, Scotland, FK1 5QE

  • Pfizer Investigational Site

    Fowey, Cornwall, PL23 1DT

  • Pfizer Investigational Site

    Glasgow, G51 4TF

  • Pfizer Investigational Site

    Hertfordshire, WD25 0EA

  • Pfizer Investigational Site

    Hinckley, Leicestershire, LE10 2SE

  • Pfizer Investigational Site

    Leatherhead, Surrey, KT24 6QT

  • Pfizer Investigational Site

    London, SE5 9RS

  • Pfizer Investigational Site

    London, W1P 9LL

  • Pfizer Investigational Site

    Mortimer, Reading, RG7 2BH

  • Pfizer Investigational Site

    Northants, NN8 4RW

  • Pfizer Investigational Site

    Northwood, Middlesex, HA6 2RN

  • Pfizer Investigational Site

    Penzance, Cornwall, TR18 4JH

  • Pfizer Investigational Site

    Plymouth, Devon, PL5 3JB

  • Pfizer Investigational Site

    Plymouth, PL6 8DH

  • Pfizer Investigational Site

    Sheffield, South Yorkshire, S7 2DW

  • Pfizer Investigational Site

    Swansea, SA6 6NL

  • Pfizer Investigational Site

    Swindon, SN25 4YZ

  • Pfizer Investigational Site

    West Didsbury, Manchester, M20 2LR

  • Pfizer Investigational Site

    Winterton, Scunthorpe, DN15 9TA

  • Pfizer Investigational Site

    Worthing, West Sussex, BN11 2DH

Other trials in United Kingdom

About this study

Official title: A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.

To explore the effects of fesoterodine when used in a flexible dose manner

Being tested
Fesoterodine
Keywords
Fesoterodine, Open Label, Flexible Dose, OAB
Medical subject headings
Urinary Bladder, Overactive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FesoterodineDrug

    Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated

Study groups in NCT00806494
Study groupRoleWhat they receive
Treatment ArmExperimentalFesoterodine 4mg, escalating to 8mg as required
Receives: Drug: Fesoterodine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12

    The number of micturitions was measured by the 3-day bladder diary completed for the 3 consecutive days preceding each clinic visit. The mean number of micturitions per 24 hours was calculated as the sum of all micturitions recorded in the diary divided by the number of days the diary was completed at that visit. Change=mean at observation minus mean at baseline. Negative change, more specifically (ie), a decrease in number of micturitions relative to baseline=improvement.

    Measured: Baseline, Week 12

Secondary outcomes (20)
  1. Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4

    The number of micturitions was measured by the 3-day bladder diary completed for the 3 consecutive days preceding each clinic visit. The mean number of micturitions per 24 hours was calculated as the sum of all micturitions recorded in the diary divided by the number of days the diary was completed at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of micturitions relative to baseline=improvement.

    Measured: Baseline, Week 4

  2. Percentage Change From Baseline in the Number of Micturitions Per 24 Hours at Weeks 4 and 12

    Percentage change from baseline in micturitions was calculated as change in mean number of micturitions per 24 hours at that visit divided by the baseline mean number of micturitions per 24 hours, multiplied by 100.

    Measured: Baseline, Week 4 and Week 12

  3. Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12

    Nocturnal micturitions were defined as those occurring between the time the subject went to bed and the time he or she arose to start the next day. The mean number of nocturnal micturitions per 24 hours was calculated as the total number of nocturnal micturitions divided by the total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of nocturnal micturitions relative to baseline=improvement.

    Measured: Baseline, Week 4 and Week 12

  4. Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Weeks 4 and 12

    Percentage change from baseline in nocturnal micturitions was calculated as change in mean number of nocturnal micturitions per 24 hours at that visit divided by the baseline mean number of nocturnal micturitions per 24 hours, multiplied by 100.

    Measured: Baseline, Week 4 and Week 12

  5. Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 4 and 12

    UUI episodes were defined as those with a Urinary Sensation Scale (USS) rating of 5 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).

    Mean number of UUI episodes per 24 hours was calculated as total number of micturitions with USS rating of 5 divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of UUI episodes relative to baseline=improvement.

    Measured: Baseline, Week 4 and Week 12

  6. Percentage Change From Baseline in UUI Episodes Per 24 Hours at Weeks 4 and 12

    Percentage change from baseline in UUI episodes was calculated as change in mean number of UUI episodes per 24 hours at that visit divided by the baseline mean number of episodes per 24 hours, multiplied by 100.

    Measured: Baseline, Week 4 and Week 12

  7. Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 4 and 12

    Urgency episodes were defined as those with a USS rating of >=3 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Mean number of urgency episodes per 24 hours was calculated as total number of urgency episodes divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of urgency episodes relative to baseline=improvement.

    Measured: Baseline, Week 4 and Week 12

  8. Percentage Change From Baseline in Urgency Episodes Per 24 Hours at Weeks 4 and 12

    Percentage change from baseline in urgency episodes was calculated as change in mean number of urgency episodes per 24 hours at that visit divided by the baseline mean number of urgency episodes per 24 hours, multiplied by 100.

    Measured: Baseline, Week 4 and Week 12

  9. Change From Baseline in Mean Number of Nocturnal Urgency Episodes (NUEs) Per 24 Hours at Weeks 4 and 12

    NUEs were defined as those with a USS rating of >=3 in the diary, occurring between the time the participant goes to bed and the time he/she arises to start the next day. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).

    Mean number of NUEs per 24 hours was calculated as total number of NUEs divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of NUEs relative to baseline=improvement.

    Measured: Baseline, Week 4 and Week 12

  10. Percentage Change From Baseline in NUEs Per 24 Hours at Weeks 4 and 12

    Percentage change from baseline in NUEs was calculated as change in mean number of NUEs per 24 hours at that visit divided by the baseline mean number of NUEs per 24 hours, multiplied by 100.

    Measured: Baseline, Week 4 and Week 12

  11. Change From Baseline in Mean Number of Severe Urgency Episodes (SUEs) Per 24 Hours at Weeks 4 and 12

    SUEs were defined as those with a USS rating of >=4 in the diary. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine). Mean number of SUEs per 24 hours was calculated as total number of SUEs divided by total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of SUEs relative to baseline=improvement.

    Measured: Baseline, Week 4 and Week 12

  12. Percentage Change From Baseline in SUEs Per 24 Hours at Weeks 4 and 12

    Percentage change from baseline in SUEs was calculated as the change in mean number of SUEs per 24 hours at that visit divided by the baseline mean number of SUEs per 24 hours, multiplied by 100.

    Measured: Baseline, Week 4 and Week 12

  13. Change From Baseline in Mean Number of Incontinence Pads Used Per 24 Hours at Weeks 4 and 12

    The mean number of incontinence pads used per 24 hours was calculated as the total number of incontinence pads used divided by the total number of diary days collected at that visit. Change=mean at observation minus mean at baseline. Negative change, ie, decrease in number of incontinence pads used relative to baseline=improvement.

    Measured: Baseline, Week 4 and Week 12

  14. Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Weeks 4 and 12

    PPBC: self-administered, single-item, questionnaire to describe perception of participants bladder-related problems (rated on 6-point scale: 1=no problems at all, 2=some very minor, 3=some minor, 4=some moderate, 5=severe, 6=many severe problems). Score change=score at observation minus score at baseline; re-scaled to 4-point categorical variables (major improvement [score difference <=-2]; minor improvement [score difference =-1]; no change [score difference = 0]; deterioration [score difference >=1]), based on PPBC score.

    Measured: Baseline, Week 4 and Week 12

  15. Change From Baseline in Urgency Perception Scale (UPS) at Weeks 4 and 12

    UPS: self-administered, single-item questionnaire to measure participant's perception of urinary urgency (rated on 3-point scale: 1=usually not able to hold urine; 3=usually able to finish what I am doing before going to toilet without leaking). Score change=score at observation minus score at baseline; re-scaled to 3-point categorical variables (improvement [Increase of 1 or more points in difference of scores]; no change [score difference=0]; deterioration [Negative difference of scores], based on UPS score, with number of participants in each of the 3-point categories.

    Measured: Baseline, Week 4 and Week 12

  16. Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Weeks 4 and 12

    OAB-q symptom bother scale (8 items) is part of the OAB-q. Symptom bother score=sum of scores for items 1 to 8 (each symptom bother item measured on 6-point Likert scale ranging from 1 (not at all) to 6 (a very great deal). Lowest possible raw score=8; highest possible score=48. Data analyzed based on transformation of score to a 0 to 100 scale: (Actual total raw score - lowest possible value of raw score)/raw score range * 100. 0=no symptom bother, 100=high symptom bother. Change=mean score at observation minus mean score at baseline, negative change in score=improvement.

    Measured: Baseline, Week 4 and Week 12

  17. Change From Baseline in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Score at Week 12

    ICIQ-SF: self-administered questionnaire for assessment and quantification of incontinence and its impact on quality of life. ICIQ score=sum of the responses to 3 questions: How often do you leak urine? (range: 0=never to 5=all the time); How much urine do you usually leak? (range: 0=none to 6=a large amount); Overall, how much does leaking urine interfere with your everyday life? (range: 0=not at all to 10=a great deal). Score range=0 (low bother from urine leakage) to 21 (maximum bother). Negative change (decrease) from baseline in score value=reduced level of bother.

    Measured: Baseline, Week 12

  18. Number of Participants With Each Categorical Response at Week 12 for Benefit, Satisfaction and Willingness to Continue (BSW) Questionnaire

    BSW: 3-item questionnaire to assess participants perception of effect of treatment in terms of treatment benefit, satisfaction with treatment, and participants willingness to continue treatment. Response to each item recorded in dichotomous fashion (Benefit: yes/no, yes - little benefit/much benefit; Satisfaction: yes/no, yes - a little satisfied/very satisfied, no - a little dissatisfied/very dissatisfied; Willingness to continue: yes/no, yes - a little bit willing/very willing, no - a little unwilling/very unwilling).

    Measured: Week 12 (or Early Withdrawal)

  19. Percentage of Participants Reporting Satisfaction on the Treatment Satisfaction Questionnaire (TSQ) at Week 12

    TSQ: Independent component of the overactive bladder TSQ. Self- administered, 1-item measure of participant satisfaction for participants receiving treatment for OAB. The 5 categorical responses were grouped to 'Satisfied' (including 'very satisfied' and 'somewhat satisfied') and 'Dissatisfied' (including 'very dissatisfied','somewhat dissatisfied', and 'neither dissatisfied nor satisfied'). Percentage of participants reporting satisfaction included those with categorical responses of 'very satisfied' and 'somewhat satisfied'.

    Measured: Week 12 (or Early Withdrawal)

  20. Change From Baseline in King's Health Questionnaire (KHQ) Domain Scores at Week 12

    KHQ: Self-administered questionnaire containing 21 questions scored in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy, severity of urinary symptoms). Each domain was a categorical scale that was converted to a numeric score. All domains transformed to a range of 0 to 100, where 0=best outcome/response and 100=worst outcome/response. Change=mean score at Week 12 minus mean score at baseline, negative change from baseline=improvement.

    Measured: Baseline, Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2008 (estimated)
  2. Study startFeb 2009
  3. Primary completionJan 2010
  4. Study completionJan 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
331 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00806494
Sponsor's protocol ID
A0221058
Acronym
SAFINA
Status last verified
Jan 2011
First submitted
9 Dec 2008
Last updated
26 Jan 2011
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Fesoterodine in people with Urinary Bladder, Overactive, run by Pfizer at 39 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Jan 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 39 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Jan 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in